Highlights

  • June 2026 quarterly customer receipts reached $3.66 million.
  • Reported June-quarter group Revenue was $4.7 million.
  • Epsilon Pharma reported a 122% year-on-year increase in June-quarter activity.
  • The pharmacy division introduced a patient portal and a community pharmacy.
  • Cash on hand increased from $503,000 to $1,469,000 during the June quarter.

Epsilon Healthcare Limited (ASX:EPN) operates pharmaceutical contract development and manufacturing, clinical services and pharmacy operations. Its integrated healthcare model connects medicine production with patient consultations and dispensing. During 2026, the company reported rising quarterly customer receipts, activity across its Manufacturing Business and further development of its pharmacy network, alongside funding and operational considerations.

June Quarter Receipts and Revenue

For the three months ended 30 June 2026, Epsilon Healthcare (ASX:EPN) reported customer receipts of $3.66 million, an increase of 72% against the corresponding quarter. The company reported group revenue of $4.7 million for the quarter, compared with $3.3 million in the March 2026 quarter, a 43% sequential increase. Revenue and customer receipts measure different aspects of activity and should not be treated interchangeably.

The company also described an annualised revenue run rate of approximately $16 million, equivalent to about $1.33 million monthly. This was a run-rate measure based on the period, not reported full-year revenue. EPN attributed its operating activity to contract manufacturing, clinics and pharmacy services.

Pharmaceutical Manufacturing Developments

The Epsilon Pharma contract development and manufacturing organisation reported 122% year-on-year growth for the June 2026 quarter. The company cited increased manufacturing activity and continuing work with domestic and international customers. Its medicinal cannabis manufacturing permit was renewed with increased authorised production capacity, allowing scope for a higher Volume of permitted finished products.

For ASX:EPN, manufacturing expansion involves both capacity and execution. Customer contracts, production scheduling, regulatory compliance and the availability of raw materials influence the conversion of production opportunities into revenue. The company reported Investment in active pharmaceutical ingredients and consumables to support manufacturing volumes.

Clinics, Pharmacy and Patient Access

Epsilon Clinics reported ongoing patient consultations and repeat engagement in the June quarter. Epsilon Healthcare (ASX:EPN) also introduced a dedicated digital patient portal for ordering, dispensing and patient management within its pharmacy business in the second quarter of 2026. A first full-service community pharmacy opened in Newtown, Sydney, broadening the division beyond digital services.

The pharmacy division was described as generating $2.3 million in annualised revenue. That annualised figure does not represent completed financial-year revenue. The combination of telehealth consultations, medicine dispensing and manufacturing is intended to connect different parts of EPN’s operating platform; the financial contribution of each division remains important to assess separately.

Cash Position and Funding Considerations

Cash on hand at 30 June 2026 was $1,469,000, compared with $503,000 in the preceding quarter. In the June quarter, customer receipts were $3,659,000 and product manufacturing and operating payments totalled $1,750,000. Staff payments were $935,000, while administration and corporate payments were $607,000.

Epsilon Healthcare (ASX:EPN) also disclosed changes to its Debt arrangements in 2026, including a new unsecured debt Facility of up to $1.72 million with a final Maturity date of 31 December 2027. Working-capital demands, financing costs and the timing of customer payments remain relevant when considering reported revenue and cash availability.

Key Insights

Epsilon Healthcare (ASX:EPN) recorded higher quarterly receipts and revenue during 2026 while developing manufacturing, clinical and pharmacy activities. The distinction between actual financial results and annualised measures remains important. Manufacturing utilisation, patient activity, cash movements and contractual execution provide practical measures of how its operating model develops.